VICTRELIS CAPSULE

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

BOCEPREVIR

Dostupno od:

MERCK CANADA INC

ATC koda:

J05AP03

INN (International ime):

BOCEPREVIR

Doziranje:

200MG

Farmaceutski oblik:

CAPSULE

Sastav:

BOCEPREVIR 200MG

Administracija rute:

ORAL

Jedinice u paketu:

14/168

Tip recepta:

Prescription

Područje terapije:

HCV Antivirals

Proizvod sažetak:

Active ingredient group (AIG) number: 0152945001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2017-01-10

Svojstava lijeka

_VICTRELIS_
®
_ (boceprevir) _
_Page 1 of 64 _
PRODUCT MONOGRAPH
VICTRELIS
®
boceprevir
200 mg capsule
Hepatitis C Virus (HCV) Protease Inhibitor (PI)
MERCK CANADA INC.
Date of Revision:
16750, route Transcanadienne
May 27, 2015
Kirkland, QC Canada H9H 4M7
http://www.merck.ca
SUBMISSION CONTROL NO: 181892
_VICTRELIS_
®
_ (boceprevir) _
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNING AND PRECAUTIONS
...................................................................................
5
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
17
DOSAGE AND ADMINISTRATION
.............................................................................
24
OVERDOSAGE
...............................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 27
STORAGE AND STABILITY
.........................................................................................
29
SPECIAL HANDLING INSTRUCTIONS
......................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 30
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.........................................................................
31
CLINICAL TRIALS
.......................